Gary Chen, MD
Internal Medicine · Brooklyn, NYNPI 1902978141
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 298 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,551 and has fallen 68.4% since, to $807 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 298 payments — averaging $26.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- AstraZeneca$1K
- Sanofi-aventis U.S. LLC$554
- GSK$539
- Johnson & Johnson$431
- Boston Scientific$413
- plus $3K from 28 others
What the payments were for
- Food & beverage$7,84199%
- Education$1121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 59 | $1,679 |
| AstraZeneca | 57 | $1,483 |
| Sanofi-aventis U.S. LLC | 29 | $554 |
| GSK | 24 | $539 |
| Johnson & Johnson | 15 | $431 |
| Boston Scientific | 3 | $413 |
| Amarin Pharma, Inc. | 31 | $406 |
| Angiodynamics, Inc. | 2 | $260 |
| Nestle Healthcare Nutrition Inc. | 11 | $183 |
| Bayer | 2 | $172 |
| AbbVie(2 entities) | 11 | $169 |
| Pfizer | 4 | $162 |
| Abbott | 1 | $136 |
| Medtronic | 1 | $135 |
| Sirtex Medical Inc | 1 | $134 |
| Boehringer Ingelheim | 1 | $125 |
| Avanir Pharmaceuticals, Inc. | 1 | $125 |
| Microvention, Inc. | 1 | $117 |
| Astellas Pharma US Inc | 5 | $94 |
| Intra-sana Laboratories | 4 | $82 |
| Aimmune Therapeutics, Inc. | 4 | $78 |
| Kowa Pharmaceuticals America, Inc. | 4 | $63 |
| Lilly USA, LLC | 4 | $53 |
| Amgen | 3 | $49 |
| Seqirus USA Inc | 3 | $46 |
| Hikma Pharmaceuticals USA | 3 | $42 |
| Novartis | 3 | $42 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
| Corcept Therapeutics | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Novo Nordisk | 2 | $26 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vemlidy$600
- XARELTO$250
- Kerendia$150
- WATCHMAN Access System$144
- OPTICROSS$144
- AVEIR$136
- AngioDynamics$135
- Pipeline$135
- ELIQUIS$135
- SIR-Spheres Microspheres$134
- BEXSERO$125
- SYNERGY$125
- Epclusa$125
- AIRSUPRA$125
- Nanoknife$125
- JARDIANCE$125
- NUEDEXTA$125
- WEB Aneurysm Embolization System$117
- Sofia 6F-125cm STR$117
- HydroSoft 3D$117
How this compares
$7,954 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Epolamine | 1,845 | $1,487,802 |
| VascepaIcosapent Ethyl | 1,674 | $674,638 |
| XareltoRivaroxaban | 231 | $187,012 |
| Diclofenac Sodium | 324 | $176,890 |
| VemlidyTenofovir Alafenamide | 117 | $168,447 |
| Ursodiol | 226 | $167,522 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 224 | $150,788 |
| Mometasone Furoate | 1,258 | $108,830 |
| Bepotastine Besilate | 869 | $94,945 |
| Clobetasol EmollientClobetasol Propionate/Emoll | 860 | $94,307 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 115 | $93,350 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 90 | $61,803 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 50 | $56,937 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $55,646 |
| Omega-3 Acid Ethyl Esters | 566 | $52,354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Farxiga, Nexium | $1,483 | $213,063341 claims |
| Johnson & JohnsonXarelto | $431 | $187,012231 claims |
| GileadVemlidy | $1,679 | $168,447117 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $554 | $56,93750 claims |
| AbbVieRestasis, Synthroid | $169 | $56,628254 claims |
| GSKTrelegy Ellipta | $539 | $55,64681 claims |
| Aimmune Therapeutics, Inc.Zenpep | $78 | $51,28953 claims |
| PfizerEliquis | $162 | $43,84661 claims |
| Astellas Pharma US IncMyrbetriq | $94 | $39,93674 claims |
| AmgenProlia | $49 | $17,93311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Brooklyn
- Bruce BergerBrooklyn$3.4M
- Jesi RamoneBrooklyn$627K
- Manish ParikhBrooklyn$236K
- Samuel UterBrooklyn$136K
- David DoveEast Hampton$12.3M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.